Organizational and management solutions to control the spread of COVID-19
- Authors: Trunin A.O1, Chudinov I.K1, Lebedeva V.O1, Aleshina D.A1, Ilina A.A1, Shirobokov Y.E2, Melerzanov A.V1,3
-
Affiliations:
- Moscow Institute of Physics and Technology (National Research University)
- Samara State Medical University, Ministry of Health of Russia
- N.A. Semashko National Research Institute of Public Health
- Issue: Vol 32, No 7 (2021)
- Pages: 5-11
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/114450
- DOI: https://doi.org/10.29296/25877305-2021-07-01
- ID: 114450
Cite item
Abstract
Full Text
About the authors
A. O Trunin
Moscow Institute of Physics and Technology (National Research University)
I. K Chudinov
Moscow Institute of Physics and Technology (National Research University)
V. O Lebedeva
Moscow Institute of Physics and Technology (National Research University)
D. A Aleshina
Moscow Institute of Physics and Technology (National Research University)
A. A Ilina
Moscow Institute of Physics and Technology (National Research University)
Ya. E Shirobokov
Samara State Medical University, Ministry of Health of Russia
A. V Melerzanov
Moscow Institute of Physics and Technology (National Research University); N.A. Semashko National Research Institute of Public Health
Email: melerzanov.av@mipt.ru
References
- Cowling B.J. et al. Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. Lancet Public Health. 2020; 5: 279-88. doi: 10.1101/2020.03.12.20034660
- Ghosh A., Nundy S., Mallick T.K. How India is dealing with COVID-19 pandemic. Sensors International. 2020; 1: 100021. doi: 10.1016/j.sintl.2020.100021
- India under COVID-19 lockdown. Lancet. 2020; 395 (10233): 1315. doi: 10.1016/S0140-6736(20)30938-7. URL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30938-7/fulltext
- Meunier T.A.J. Full lockdown policies in Western Europe countries have no evident impacts on the COVID-19 epidemic. MedRxiv. 2020. doi: 10.1101/2020.04.24.20078717
- Xiao Y., Torok M.E. Taking the right measures to control COVID-19. Lancet Infect Dis. 2020; 5: 523-24. doi: 10.1016/s1473-3099(20)30152-3. URL: https://www.thelancet.com/article/S1473-3099(20)30152-3/fulltext
- Howard J. et al. An evidence review of face masks against COVID-19. Proc Nat Acad Sci. 2021; 118 (4). e2014564118. doi: 10.1073/pnas.2014564118.
- Борисевич С.В., Сизикова Т.Е., Лебедев В.Н. Пандемия COVID-19: анализ возможных сценариев развития эпидемии заболевания в России. Вестник войск РХБ защиты. 2020; 4 (2): 116-30 doi: 10.35825/2587-5728-2020-4-2-116-130
- Матвеев А.В. Математическое моделирование оценки эффективности мер против распространения эпидемии COVID-19. Национальная безопасность и стратегическое планирование. 2020; 1: 23-39 doi: 10.37468/2307-1400-2020-1-23-39
- Применение масок в условиях COVID-19. Временные рекомендации всемирной организации здравоохранения [Interim recommendations of the World Health Organization (in Russ)]. URL https://apps.who.int/iris/bitstream/handle/10665/337199/WHO-2019-nCov-IPC_Masks-2020.5-rus.pdf
- Sickbert-Bennett E.E. et al. Filtration efficiency of hospital face mask alternatives available for use during the COVID-19 pandemic. JAMA Intern Med. 2020; 180 (12): 1607-12. doi: 10.1001/jamainternmed.2020.4221
- Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) Министерства здравоохранения Российской Федерации (Версия 10) URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/054/588/original/Временные_МР_COVID-19_%28v.W%29-08.02.2021_%281%29.pdf
- Анциферов М.Б. и др. Клинический протокол лечения больных новой коронавирусной инфекцией COVID-19. Под ред. А.И. Хрипуна М.: ГБУ «НИИОЗММ ДЗМ; 2020.
- Гайсенок О.В. Применение ингибиторов вирусных РНК-полимераз в сочетании с ингибитором фузии в лечении пациентов с COVID-19: гипотеза. Вопросы вирусологии. 2020; 65 (3): 167-75 doi: 10.36233/0507-4088-2020-65-3-167-175
- Козлов В.А., Савченко А.А., Кудрявцев И.В. и др. Клиническая иммунология. Красноярск: Поликор, 2020; 386 с. doi: 10.17513/np.438
- Coomes E.A., Haghbayan H. Favipiravir, an antiviral for COVID-19? J. Antimicrob Chemother. 2020; 75 (7): 2013-4. doi: 10.1093/jac/dkaa171
- Ghasemnejad-Berenji M., Pashapour S. Favipiravir and COVID-19: a simplified summary. Drug Res (Stuttg). 2021; 71 (3): 166-70. doi: 10.1055/a-1296-7935
- Udwadia Z. F. et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J. Infect Dis. 2021; 103: 62-71. doi: 10.1016/j.ijid.2020.11.142
- Sinha N., Balayla G. Hydroxychloroquine and COVID-19. Postgrad Med. 2020; 96 (1139): 550-5. doi: 10.1136/postgradmedj-2020-137785
- Meo S.A., Klonoff D.C., Akram J. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. Eur Rev Med Pharmacol Sci. 2020; 24 (8): 4539-47. doi: 10.26355/eurrev_202004_21038
- Boulware D.R. et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N. Engl J. Med. 2020; 383 (6): 517-25. doi: 10.1056/NEJMoa2016638
- Протокол лечения COVID-19 медицинского центра МГУ [The protocol of treatment of COVID-19 of the MSU medical center (in Russ)]. URL: http://www.mc.msu.ru/protokol-mnoc.pdf
- Мареев В.Ю. и др. ПУльс-Терапия стероидными гормоНамИ больных с Коронавирусной пневмонией (COVID-19), системным воспалением и риском венозных тромбозов и тромбоэмболий (исследование ПУТНИК). Кардиология. 2020; 60 (6): 15-29 doi: 10.18087/cardio.2020.6.n1226
- Erensoy S. SARS-CoV-2 and Microbiological Diagnostic Dynamics in COVID-19 Pandemic. Mikrobiyol bul. 2020; 54 (3): 497-509. DOI: 10.5578/ mb.69839
- Zitek T. The appropriate use of testing for COVID-19. West J. Emerg Med. 2020; 21 (3): 470. doi: 10.5811/westjem.2020.4.47370
- Cheng M.P. et al. Diagnostic testing for severe acute respiratory syndrome-related coronavirus 2: a narrative review. Ann Intern Med. 2020; 172 (11): 726-34. doi: 10.7326/M20-1301
- Chau C.H., Strope J.D., Figg W.D. COVID-19 Clinical Diagnostics and Testing Technology. Pharmacotherapy. 2020; 40 (8): 857-68. DOI: 10.1002/ phar.2439
- Deeks J.J. et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020; 6: CD013652. doi: 10.1002/14651858.CD013652
- Tregoning J.S. et al. Vaccines for COVID-19. Clin Exp Immunol. 2020; 202 (2): 162-92. doi: 10.1111/cei.13517
- Chung J.Y., Thone M.N., Kwon Y.J. COVID-19 vaccines: The status and perspectives in delivery points of view. Adv Drug DelivRev. 2021; 170: 1-25. doi: 10.1016/j.addr.2020.12.011
- Гудима Г.О., Хаитов Р.М., Кудлай Д.А. и др. Молекулярноиммунологические аспекты диагностики, профилактики и лечения коронавирусной инфекции. Иммунология. 2021; 42 (3): 198-210 doi: 10.33029/0206-4952-2021-42-3-198-210
- Korber B. et al. Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020; 182 (4): 812-27. doi: 10.1016/j.cell.2020.06.043
- Yu H.Q., Sun B.Q., Fang Z.F. et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur Respir J. 2020; 56 (2): 2001526. doi: 10.1183/13993003.01526-2020
- Weissman D. et al. D614G spike mutation increases SARS CoV-2 susceptibility to neutralization. Cell Host Microbe. 2021; 29 (1): 23-31. doi: 10.1016/j.chom.2020.11.012